Itacitinib - CAS 1334298-90-6
Catalog number: 1334298-90-6
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C26H23F4N9O
Molecular Weight:
553.51
COA:
Inquire
Targets:
JAK
Description:
Itacitinib is a potent Janus kinase-1 inhibitor under the development of AstraZeneca and Incyte Corporation. Itacitinib can inhibit OCT2-mediated uptake of creatinine as well as MATE1-/MATE2-K-mediated efflux of creatinine. Now it is in Phase II trials for the treatment of Graft-versus-host disease; Non-small cell lung cancer.
Purity:
98%
Appearance:
Powder
Synonyms:
INCB 039110;2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile
Solubility:
DMSO: > 35 mg/Ml
Storage:
-20°C Freezer
MSDS:
Inquire
Application:
Graft-versus-host disease; Non-small cell lung cancer
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Milligrams-Grams
InChIKey:
KTBSXLIQKWEBRB-UHFFFAOYSA-N
InChI:
1S/C26H23F4N9O/c27-20-18(1-7-32-22(20)26(28,29)30)24(40)37-9-3-17(4-10-37)38-13-25(14-38,5-6-31)39-12-16(11-36-39)21-19-2-8-33-23(19)35-15-34-21/h1-2,7-8,11-12,15,17H,3-5,9-10,13-14H2,(H,33,34,35)
Canonical SMILES:
Fc1c(ccnc1C(F)(F)F)C(=O)N2CCC(CC2)N3CC(CC#N)(C3)n4cc(cn4)c5ncnc6[nH]ccc56
Current Developer:
AstraZeneca; Incyte Corporation
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related JAK Products


CAS 960201-81-4 SD 1008

SD 1008
(CAS: 960201-81-4)

SD 1008 is a JAK2/STAT3 signaling pathway inhibitor that inhibits activation of STAT3, JAK2 and Src. SD 1008 induces apoptosis in cell lines expressing constitu...

CAS 1208319-27-0 Oclacitinib maleate

Oclacitinib maleate
(CAS: 1208319-27-0)

Oclacitinib maleate was the first selective Janus kinase (JAK) inhibitor to be developed for dogs. Oclacitinib is most potent at inhibiting JAK1 (IC50=10 nM).

PF-956980
(CAS: 1262832-74-5)

PF-956980, a close analogue of Tofacitinib, is a JAK3-selective inhibitor used as an anti-inflammatory agent. Besides, some studies showed that PF-956980 striki...

CAS 1056636-06-6 CYT387 sulfate salt

CYT387 sulfate salt
(CAS: 1056636-06-6)

CYT387 sulfate is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3.

CAS 916742-11-5 R-932348

R-932348
(CAS: 916742-11-5)

A dual JAK/SYK inhibitor that can be used to treat diseases and disorders of the eye.

CAS 58753-54-1 ZM 39923 hydrochloride

ZM 39923 hydrochloride
(CAS: 58753-54-1)

ZM 39923 hydrochloride is a potent and selective inhibitor of Janus tyrosine kinase 3 (JAK3) (pIC50 = 7.1, 5.6, 4.4, and < 5.0 for JAK3, EGFR, JAK1 and CDK4, re...

CAS 1092578-46-5 (3R,4S)-Tofacitinib

(3R,4S)-Tofacitinib
(CAS: 1092578-46-5)

Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.

CAS 857064-38-1 WP1066

WP1066
(CAS: 857064-38-1)

WP1066 is a Stat3 inhibitor and JAK2 inhibitor. WP1066 is also a novel analogue of the JAK2 inhibitor AG490, in JAK2 V617F-positive erythroleukemia HEL cells a...

BBT594
(CAS: 882405-89-2)

BBT594, also called as NVP-BBT594, a dihydroindole compound, originally developed as an inhibitor of wild-type and T315I-mutant BCR–ABL1, and then subsequently ...

CAS 1450881-55-6 SAR-20347

SAR-20347
(CAS: 1450881-55-6)

SAR-20347 is a small molecule inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC50s of 0.6, 23, 26 and 41 nM, respectively. SAR-20347 dose dependently (1 nM-10 μM) ...

CAS 540737-29-9 Tofacitinib Citrate

Tofacitinib Citrate
(CAS: 540737-29-9)

Tofacitinib (trade name Xeljanz, formerly tasocitinib, CP-690550) is a drug discovered and developed by Pfizer. It is currently approved for the treatment of rh...

CAS 82058-16-0 NSC 33994

NSC 33994
(CAS: 82058-16-0)

NSC-33994 is a selective inhibitor of JAK2 with IC50 of 60 nM.

CAS 202475-60-3 JANEX-1

JANEX-1
(CAS: 202475-60-3)

A cell-permeable, reversible, potent, ATP-competitive, and specific inhibitor of JAK3 (Janus family kinase 3; IC50 = 78 µM). Has no effect on JAK1, JAK2, or Zap...

CAS 935666-88-9 AZD-1480

AZD-1480
(CAS: 935666-88-9)

AZD1480 is an orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. AZD1480 inhibits JAK2 activation, leadin...

CAS 1260181-14-3 TCS 21311

TCS 21311
(CAS: 1260181-14-3)

TCS 21311 is a potent JAK3 inhibitor (IC50 = 8 nM) with selectivity for JAK3 over JAK1, JAK2 and TYK2 (IC50 = 1017, 2550 and 8055 nM, respectively). It also inh...

CAS 944118-01-8 Peficitinib

Peficitinib
(CAS: 944118-01-8)

Peficitinib, also known as ASP015K and JNJ-54781532, is a novel potent JAK inhibitor, which demonstrated potent efficacy in adjuvant-induced arthritis model in ...

CAS 1092939-16-6 Ruxolitinib sulfate

Ruxolitinib sulfate
(CAS: 1092939-16-6)

Ruxolitinib sulfate (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1...

NS-018 hydrochloride
(CAS: 1239358-85-0)

The hydrochloride salt form of NS-018 which is a selective JAK2 as well as Src family tyrosine kinases inhibitor that could probably induce the apoptosis of tum...

CAS 1187594-09-7 Baricitinib

Baricitinib
(CAS: 1187594-09-7)

Baricitinib is a selective and orally bioactive inhibitor of JAK1 and JAK2. Baricitinib inhibits intracellular signaling of multiple proinflammatory cytokines i...

CAS 1204918-72-8 SB1317

SB1317
(CAS: 1204918-72-8)

SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cel...

Quick Inquiry

Verification code

Featured Items